The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Richard Ross, Managing Director and Head of Technical Analysis at Evercore ISI, takes a technical look at three stocks he says are about to break out.
Jim Cramer sees signs everywhere that the worst is over for pharma.
Jim Cramer sees signs everywhere that the worst is over for pharma. He goes down his playbook of pharma signs, and how to play it.
Some 30 American companies were recognized for their efforts to boost diversity and inclusion.
It's the busiest earnings week of the quarter. The HR experts give a preview
The FMHR traders reveal their final trades during this busy earnings week.
Jim Cramer provides his opinion on how to diversify various investor portfolios, including the great FB vs AAPL conundrum.
David Kostin, Goldman Sachs Chief U.S. Equity Strategist, talks about the current state of the markets and the risks for first quarter earnings.
Jim Cramer details how Washington has set out to stop the American investor.
Jim Cramer rattles off his take on caller favorite stocks, including this popular pharmaceutical stock that has Cramer as a buyer.
Mad Money host Jim Cramer believes presidential politics will have no impact on this high-profile stock.
"Halftime Report" trader Pete Najarian bought shares of a pharma giant on Wednesday after spotting unusual options activity.
Jim Cramer admitted he was totally wrong about this stock. He is now a believer, and thinks you should be, too.
The FMHR traders take their positions on four stocks making news today, including Bristol-Myers moving higher after Barron's said the stock could rise 25 percent in 2016.
U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.
Earnings forecast may be dim, but these five stocks are winners, says Goldman Sachs' David Kostin.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.